 |
N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide |
|---|---|
| Trade Name | |
| Orphan Indication | Stages IIB-IV melanoma |
| USA Market Approval | USA |
| USA Designation Date | 2004-08-13 00:00:00 |
| Sponsor | Pfizer, Inc.;50 Pequot, 6025-A3106;New London, Connecticut, 06320 |
